Citations (12)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Rudolph M Navari. (2019) The safety of rolapitant for the treatment of nausea and vomiting associated with chemotherapy. Expert Opinion on Drug Safety 18:12, pages 1127-1132.
Read now
Read now
Rudolph M Navari. (2017) Cancer patients at high risk for chemotherapy-induced nausea and vomiting – prediction assessments/tools. Expert Review of Quality of Life in Cancer Care 2:2, pages 103-108.
Read now
Read now
Piotr K Janicki. (2016) Management of acute and delayed chemotherapy-induced nausea and vomiting: role of netupitant–palonosetron combination. Therapeutics and Clinical Risk Management 12, pages 693-699.
Read now
Read now
Rudolph M. Navari. (2016) The safety of antiemetic medications for the prevention of chemotherapy-induced nausea and vomiting. Expert Opinion on Drug Safety 15:3, pages 343-356.
Read now
Read now
Rudolph M Navari. (2015) Rolapitant for the treatment of chemotherapy-induced nausea and vomiting. Expert Review of Anticancer Therapy 15:10, pages 1127-1133.
Read now
Read now
Articles from other publishers (7)
Bharat Vaswani, Palanki Satya Dattatreya, Sagar Bhagat, Saiprasad Patil & Hanmant Barkate. (2021) The effectiveness of NEPA in the prevention of chemotherapy-induced nausea vomiting among chemo naive patients in an Indian setting. BMC Cancer 21:1.
Crossref
Crossref
Marc Botteman, Katharina Nickel, Shelby Corman, Marco Turini & Gary Binder. (2019) Cost-effectiveness of a fixed combination of netupitant and palonosetron (NEPA) relative to aprepitant plus granisetron (APR + GRAN) for prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a trial-based analysis. Supportive Care in Cancer 28:2, pages 857-866.
Crossref
Crossref
R. Ienca, C. Giardiello, A. Scozzarro, R. Schiano di Cola, N. Di Lorenzo, Girish Juneja, G. Lopez & F. Badiuddin. (2019) Improving Nausea and Vomiting Post-Elipse Balloon: a Novel Single-Dose Regimen of 300 mg Netupitant/0.5 mg Palonosetron Hydrochloride. Obesity Surgery 29:9, pages 2952-2956.
Crossref
Crossref
James Gilmore & Alberto Bernareggi. (2019) Complementary Pharmacokinetic Profiles of Netupitant and Palonosetron Support the Rationale for Their Oral Fixed Combination for the Prevention of Chemotherapy-Induced Nausea and Vomiting. The Journal of Clinical Pharmacology 59:4, pages 472-487.
Crossref
Crossref
John A. Rudd, Sze W. Chan, Man P. Ngan, Longlong Tu, Zengbing Lu, Claudio Giuliano, Emanuela Lovati & Claudio Pietra. (2018) Anti-emetic Action of the Brain-Penetrating New Ghrelin Agonist, HM01, Alone and in Combination With the 5-HT3 Antagonist, Palonosetron and With the NK1 Antagonist, Netupitant, Against Cisplatin- and Motion-Induced Emesis in Suncus murinus (House Musk Shrew). Frontiers in Pharmacology 9.
Crossref
Crossref
John A. Rudd, Man P. Ngan, Zengbing Lu, Guy A. Higgins, Claudio Giuliano, Emanuela Lovati & Claudio Pietra. (2016) Profile of Antiemetic Activity of Netupitant Alone or in Combination with Palonosetron and Dexamethasone in Ferrets and Suncus murinus (House Musk Shrew). Frontiers in Pharmacology 7.
Crossref
Crossref
Yu Zhou, Jiang Wang, Zhanni Gu, Shuni Wang, Wei Zhu, José Luis Aceña, Vadim A. Soloshonok, Kunisuke Izawa & Hong Liu. (2016) Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas. Chemical Reviews 116:2, pages 422-518.
Crossref
Crossref